At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Feasibility Study of "Early" Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms
In Brief
A Phase 2 clinical trial evaluating Cladribine, Cyclosporine, and 12 other interventions for Blasts 10 Percent or More of Bone Marrow Nucleated Cells and 8 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This clinical trial studies how well early stem cell transplantation works in treating patients with high-grade myeloid neoplasms that has come back after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as filgrastim, cladribine, cytarabine and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor peripheral blood cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells. Early stem cell transplantation may result in more successful treatment for patients with high-grade myeloid neoplasms.
Study Details
Timeline
Interventions
Given IV
Given PO
Given IV
Given SC
Undergo allogeneic hematopoietic stem cell transplantation
Correlative studies
Given IV
Given IV
Given PO
Ancillary studies
Given PO
Undergo TBI
Given IV